medigraphic.com
ISSN 1561-2937 (Print)

2020, Number 4

<< Back Next >>

Rev Cubana Cardiol Cir Cardiovasc 2020; 26 (4)

Neutrophil lymphocyte index, heart and COVID-19

Rodríguez BS, Pérez YLM, Aguilar MJM

Language: Spanish
References: 37
Page: 1-6
PDF size: 154.68 Kb.


ABSTRACT

Infection with the new SARS-CoV2 coronavirus, which causes COVID-19 disease, causes myocardial damage in a significant subgroup of patients. This has been related to the presence of systemic and myocardial inflammation where various inflammatory markers are involved, one of them being the lymphocyte neutrophil ratio. The objective of this article is to describe the relationship of the lymphocytic neutrophil ratio, as a cardiac biomarker, with the myocardial damage that can appear during infection by the disease. A non-systematic review of the evidence published in different databases was carried out and 37 bibliographies on the subject were selected.


REFERENCES

  1. Hendren NS, Drazner MH, Bozkurt B, Cooper, Jr. LT. Description and proposed management of the acute COVID. 19 cardiovascular syndrome. Circulation. 2020;141:1903–14. https://doi.org/10.1161/circulationaha.120.047349

  2. Li T, Lu H and Zhang W. Clinical observation and management of COVID. 19 patients. Emerg Microbes Infect. 2020;9(1):687. 90.

  3. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X et al. High expression of ACE2 receptor of 2019. nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8.

  4. Singh S, Sharma A, Arora SK. High producer haplotype (CAG) of . 863C/A, . 308G/A and . 238G/A polymorphisms in the promoter region of TNF. alpha gene associate with enhanced apoptosis of lymphocytes in HIV. 1 subtype C infected individuals from North India. PLoS One. 2014;9(5):e98020

  5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395: 497. 06. doi: 10.1016/S0140. 6736(20)30183. 5

  6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395: 507. 13. DOI:https://doi.org/10.1016/S01406736(20)30211. 7

  7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirus. infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061. 69.doi:10.1001/jama.2020.1585

  8. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; doi:10.1001/jamainternmed.2020.0994

  9. Qin C , Zhou L , Hu Z, Zhang S, Yang S, TaoY et al . Dysregulation of immune response in patients with COVID. 19 in Wuhan, China. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2020. https://doi.org/10.1093/cid/ciaa248

  10. Deng Y, Liu W, Liu K, Yuan. Yuan F, Jin S, Ling Z et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID. 19) in Wuhan, China: a retrospective study. Chin Med J. 2020;133:1261. 67.

  11. Shi S, Qin M, Shen B, Cai Y, Liu T, Fan Yang, et al. Association of cardiac injury with mortality in hospitalized patients with COVID. 19 in Wuhan, China. JAMA Cardiol. 2020.doi:10.1001/jamacardio.2020.0950.

  12. Guo T, Fan Y, Chen M, Chen M, Wu X, Zhang L et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID. 19). JAMA Cardiol. 2020:e201017.doi:10.1001/jamacardio.2020.1017.

  13. Faria SS , Fernandes PJ , Silva MJ, Lima VC, Fontes, Freitas. Junior R et al. The neutrophil. to. lymphocyte ratio: a narrative review. Ecancermedicalscience. 2016;10:702 . doi:10.3332/ecancer.2016.702

  14. Ridker PM, Everett BM, Thuren T, J.G. MacFadyen, W.H. Chang, C. Ballantyne et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31.doi: 10.1056/NJJMoa1707914.

  15. Westman PC, Lipinski MJ, Luger D, Waksman R, Bonow RO, Wu E et al. Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2016;67:2050–60. https://doi.org/10.1016/j.jacc.2016.01.073

  16. Suleiman M, Khatib R, Agmon Y, Mahamid R, Boulos M, Kapeliovich M et al. Early inflammation and risk of long. term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C. reactive protein. J Am Coll Cardiol. 2006;47:962. 8.

  17. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S et al. Lipoprotein. associated phospholipase A (2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375:1536–44. DOI:https://doi.org/10.1016/S0140. 6736(10)60319. 4

  18. Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes Jr D, O’Neill WW et al. Pexelizumab for acute ST. elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA. 2007;297:43–51. doi:10.1001/jama.297.1.43

  19. Uzma Gul, Sajjad Hussain, Rubab Munir and Azhar Mehmood Kayani. Neutrophil Lymphocyte Ratio: A prognostic marker in acute ST elevation myocardial infarction. Journal of the college of physicians and surgeons Pakistan. 2017;27(1):4. 7

  20. Ema Tahto, Radivoj Jadric, Lamija Pojskic and Esmeralda Kicic. Neutrophil. to. lymphocyte ratio and Its relation with markers of inflammation and Myocardial necrosis in patients with acute coronary syndrome. Med arch. 2017;71(5):31215. doi: 10.5455/medarh.2017.71.312. 315

  21. Avci BS, Avci A, Dönmez Y, Kaya A, Gülen M, Özer AL et al. The effectiveness of neutrophil. lymphocyte ratio in predicting in. hospital mortality in non. ST. elevation myocardial infarction. Emergency medicine international. 2020; Article ID 8718304. https://doi.org/10.1155/2020/8718304

  22. Adam J. Nelson, Stephen Nicholls, A. Lincoff, Venu Menon, Jeffrey Riesmeyer, Giacomo Ruotolo et al. Elevated levels of the neutrophil to lymphocyte ratio predicts incidence of major adverse cardiovascular events in high risk patients: insights from accelerate. JACC. 2018;71(11):e33 DOI:10.1016/S0735. 1097(18)30574. 6

  23. Cappannoli L, Scacciavillani R, Iannaccone G, Anastasia G, Di Giusto F, Loria V et al. 2019 Novel. coronavirus: Cardiovascular Insights about Risk Factors, Myocardial Injury, Therapy and Clinical Implications. Chronic Dis Transl Med. 2020. doi: 10.1016/j.cdtm.2020.06.002

  24. Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R et al. Prevalence and impact of cardiovascular metabolic diseases on COVID. 19 in China. Clin res cardiol. 2020;109(5):531. 38. doi: 10.1046/j.1440. 1843.2003.00522.

  25. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi. Zoccai G et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID. 19) pandemic. J Am Coll Cardiol. 2020. doi: https://doi.org/10.1016/j.jacc.2020.03.031.

  26. Giulio G. Stefanini, Matteo Montorfano, Daniela Trabattoni, Daniele Andreini, Giuseppe Ferrante, Marco Ancona et al. ST. Elevation Myocardial Infarction in Patients with COVID. 19: Clinical and Angiographic Outcomes. Circulation. 2020. https://doi.org/10.1161/CIRCULATIONAHA.120.047525.

  27. Zhe Zhua, Ting Caib, Lingyan Fanb, Kehong Loub, Xin Huab, Zuoan Huangb et al. Clinical value of immune. inflammatory parameters to assess the severity of coronavirus disease 2019. International Journal of Infectious Diseases 2020;95:332–39.

  28. Liu J, Li S, Liu J, Liang B, Wang X, Wang H et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARSCoV. 2 infected patients. MedRxiv 2020.doi: https://doi.org/10.1101/2020.02.16.20023671

  29. Wang D, Hu B, Hu Ch, Zhu F, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus. infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061. 69. doi:10.1001/jama.2020.1585.

  30. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li Ch et al. Neutrophil. to. lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage. medRxiv 2020. DOI: https://doi.org/10.1101/2020.02.10.20021584

  31. Bicheng Zhang, Xiaoyang Zhou, Chengliang Zhu, Fan Feng, Yanru Qiu, Jia Feng et al. Immune phenotyping based on neutrophil. to. lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID. 19. MedRxiv. 2020. https://doi.org/10.1101/2020.03.12.20035048.

  32. Francisco Alejandro Lagunas‐Rangel. Neutrophil‐to‐lymphocyte ratio and lymphocyte‐to‐C‐reactive protein ratio in patients with severe coronavirus disease 2019 (COVID‐19): A meta‐analysis. J Med Virol. 2020. https://doi.org/10.1002/jmv.25819.

  33. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang H.H.X et al.Neutrophil. to. lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID. 19. Journal of Infection. 2020;17:28 https://doi.org/10.1016/j.jinf.2020.04.002

  34. Suilbert Rodríguez Blanco, Abel Y. Leyva Quert, José M. Aguilar Medina, Pedro M. Collazo, Enmanuel Hernández Váldes, Juan Carlos Perez et al. Valor del índice neutrófilo. linfocitario en la predicción de la severidad de enfermedad arterial coronaria. Revista Cubana de Cardiología y Cirugía Cardiovascular. 2020;26(1):1. 6

  35. Suilbert Rodríguez Blanco, Abel Y Leyva Quert y José M Aguilar Medina. Índice neutrófilo. linfocitario en la predicción de trombosis temprana del stent. Revista Argentina de Cardioangiología Intervencionista. 2020;(01):0017. 0020 Doi: 10.30567/RACI/202001/0017. 0020

  36. Park JJ, Jang HJ, Oh IY, Yoon CH, Suh JW, Cho YS et al. Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST. elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2013;111:636–42. doi: 10.1016/j.amjcard.2012.11.012

  37. Xiao Z, Xu C, Wang D and Zeng H. The experience of treating patients with acute myocardial infarction under the COVID. 19 epidemic. Catheter Cardiovasc Interv. 2020. https://doi.org/10.1002/ccd.28951




2020     |     www.medigraphic.com